This is the bottom line of the ongoing phase II study (NCT04553770) aiming at identifying the treatment arm with strongest signal of efficacy based on pCR between neoadjuvant deruxtecan alone or in combination with anastrozole in patients with HER2-low/HR-positive early-stage breast cancer (U.S. National Library of Medicine, 2022). This evidence concerns the gene ERBB2 and breast carcinoma.